Oppenheimer Asset Management Inc. Has $1.48 Million Stake in The Cooper Companies, Inc. (NASDAQ:COO)

Oppenheimer Asset Management Inc. reduced its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 4.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,096 shares of the medical device company’s stock after selling 823 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Cooper Companies were worth $1,480,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Ashton Thomas Securities LLC bought a new stake in shares of Cooper Companies in the 3rd quarter valued at $25,000. Covestor Ltd increased its holdings in shares of Cooper Companies by 144.9% in the third quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock worth $37,000 after acquiring an additional 200 shares in the last quarter. Byrne Asset Management LLC acquired a new stake in shares of Cooper Companies during the fourth quarter worth about $33,000. Brown Brothers Harriman & Co. raised its position in shares of Cooper Companies by 191.0% during the third quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock worth $46,000 after purchasing an additional 275 shares during the period. Finally, West Financial Advisors LLC bought a new position in shares of Cooper Companies during the 4th quarter valued at about $49,000. 24.39% of the stock is owned by institutional investors.

Cooper Companies Trading Up 1.4 %

Cooper Companies stock opened at $91.65 on Tuesday. The company has a market cap of $18.29 billion, a price-to-earnings ratio of 47.00, a P/E/G ratio of 2.25 and a beta of 1.00. The firm has a 50-day moving average of $92.63 and a 200-day moving average of $99.59. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12. The Cooper Companies, Inc. has a one year low of $84.76 and a one year high of $112.38.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Thursday, December 5th. The medical device company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.00 by $0.04. The firm had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.03 billion. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The business’s quarterly revenue was up 9.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.87 earnings per share. On average, equities analysts expect that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. StockNews.com downgraded shares of Cooper Companies from a “buy” rating to a “hold” rating in a report on Wednesday, December 11th. Needham & Company LLC reissued a “hold” rating on shares of Cooper Companies in a research report on Friday, December 6th. Citigroup cut their price objective on shares of Cooper Companies from $116.00 to $115.00 and set a “buy” rating on the stock in a research report on Friday, December 6th. Morgan Stanley lowered their target price on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating for the company in a report on Friday, December 6th. Finally, Wells Fargo & Company lifted their price target on Cooper Companies from $115.00 to $118.00 and gave the company an “overweight” rating in a research note on Friday, December 6th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $117.22.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.